Edmond DE Rothschild Holding S.A. Takes Position in Arvinas, Inc. (NASDAQ:ARVN)

Edmond DE Rothschild Holding S.A. bought a new position in shares of Arvinas, Inc. (NASDAQ:ARVN) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $1,534,000. Edmond DE Rothschild Holding S.A. owned about 0.12% of Arvinas at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ARVN. KBC Group NV lifted its stake in shares of Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after buying an additional 1,255 shares during the last quarter. Quantbot Technologies LP raised its holdings in Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after acquiring an additional 2,601 shares during the period. KLP Kapitalforvaltning AS acquired a new position in Arvinas during the 4th quarter worth $171,000. Teacher Retirement System of Texas boosted its holdings in Arvinas by 19.0% during the fourth quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company’s stock valued at $274,000 after acquiring an additional 2,280 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Arvinas by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company’s stock worth $279,000 after purchasing an additional 1,367 shares during the period. 95.19% of the stock is currently owned by institutional investors.

Insider Transactions at Arvinas

In other news, insider Noah Berkowitz sold 8,658 shares of the stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total transaction of $74,372.22. Following the sale, the insider now owns 110,023 shares in the company, valued at approximately $945,097.57. This represents a 7.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John G. Houston sold 31,338 shares of the firm’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the sale, the chief executive officer now owns 1,157,480 shares of the company’s stock, valued at approximately $19,353,065.60. This trade represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,230 shares of company stock valued at $769,402. Corporate insiders own 5.23% of the company’s stock.

Arvinas Price Performance

Shares of NASDAQ:ARVN opened at $7.03 on Wednesday. The stock has a market capitalization of $483.47 million, a price-to-earnings ratio of -2.54 and a beta of 1.95. The business’s fifty day moving average price is $14.82 and its two-hundred day moving average price is $20.39. Arvinas, Inc. has a fifty-two week low of $6.84 and a fifty-two week high of $40.16.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter in the previous year, the company posted ($2.53) earnings per share. Research analysts expect that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. BMO Capital Markets set a $20.00 target price on Arvinas and gave the company an “outperform” rating in a research note on Wednesday, March 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a research note on Friday, February 7th. Guggenheim decreased their price target on shares of Arvinas from $57.00 to $32.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. Morgan Stanley cut their price objective on shares of Arvinas from $48.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, March 13th. Finally, Wells Fargo & Company set a $26.00 target price on Arvinas and gave the stock an “overweight” rating in a research report on Wednesday, March 12th. Five research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $35.50.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.